Aspire Biopharma Holdings, Inc.
ASBP
$0.11
$0.0113.05%
NASDAQ
Recommendation
Prev Close
Volume
Avg Vol (90D)
Market Cap
Dividend & Yield
--
P/E (TTM)
--
EPS (TTM)
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 428.71% | 452.92% | 375.17% | 269.37% | -- |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 547.78% | 555.93% | 413.47% | 247.64% | -- |
| Operating Income | -547.47% | -555.93% | -413.47% | -247.64% | -- |
| Income Before Tax | -3,210.99% | -3,918.82% | -3,569.19% | -276.42% | -- |
| Income Tax Expenses | -100.00% | 100.00% | 100.00% | 100.00% | -- |
| Earnings from Continuing Operations | -3,203.00% | -3,914.76% | -3,565.44% | -276.16% | -- |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -3,203.00% | -3,914.76% | -3,565.44% | -276.16% | -- |
| EBIT | -547.47% | -555.93% | -413.47% | -247.64% | -- |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | -2,412.56% | -3,787.60% | -4,943.02% | -10,600.00% | -- |
| Normalized Basic EPS | -503.23% | -650.67% | -616.98% | -13,200.00% | -- |
| EPS Diluted | -2,412.56% | -3,787.60% | -4,943.02% | -10,600.00% | -- |
| Normalized Diluted EPS | -503.23% | -650.67% | -616.98% | -13,200.00% | -- |
| Average Basic Shares Outstanding | 9.69% | 11.37% | 13.28% | 18.01% | -- |
| Average Diluted Shares Outstanding | 9.69% | 11.37% | 13.28% | 18.01% | -- |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |